Evogene Ltd Ord (EVGN)

$0.76 -0.02 (-2.05%)
Market Cap 6.77M
Revenue (ttm) 3.85M
Net Income (ttm) -8.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220.52%
Debt to Equity Ratio 0.00
Volume 48,300
Avg Vol 111,246
Day's Range N/A - N/A
Shares Out 8.72M
Stochastic %K 22%
Beta 1.39
Analysts Strong Buy
Price Target $2.25

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commerci...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 931 1900
Fax: 972 8 946 6724
Address:
13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel
SuperBusa
SuperBusa May. 11 at 4:08 PM
$EVGN next Wednesday earings.
0 · Reply
SuperBusa
SuperBusa May. 7 at 3:49 PM
$EVGN
0 · Reply
omenkes
omenkes May. 4 at 6:53 PM
$EVGN https://www.biomicamed.com/ read the message. why have they not officially published the full results? Asco 2026 is at the end of the month. will it be published there (like in 2022, 2024)? https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS2685 - june 2, 2022 https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8631 - may 29, 2024 what will it be in 2026?
1 · Reply
omenkes
omenkes Apr. 23 at 2:41 PM
$EVGN https://www.greenqueen.com.hk/finally-foods-pre-seed-funding-molecular-farming-casein-protein-potatoes/ https://www.proteinproductiontechnology.com/post/finally-foods-closes-pre-seed-round-to-scale-plant-based-casein-production-in-potatoes Finally foods is partly owned by Evogene and the casein expression is first implementation of the evogene ai for genetic modifications. And we still are waiting for the Biomica phase 1 final results of bmc128. interim in 2024 was very promising.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 14 at 11:40 PM
$EVGN RSI: 41.67, MACD: -0.0146 Vol: 0.04, MA20: 0.82, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:26 PM
$EVGN says it has until September 28, 2026 to fix its minimum bid problem after Nasdaq's notice.
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 31 at 12:03 PM
$EVGN Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock
0 · Reply
ObsidianClaw
ObsidianClaw Mar. 31 at 9:59 AM
$EVGN 🗑️
0 · Reply
100K2022
100K2022 Mar. 25 at 10:57 PM
$EVGN looks like dud
0 · Reply
SuperBusa
SuperBusa Mar. 25 at 4:58 PM
$EVGN
0 · Reply
Latest News on EVGN
Evogene to Present at the 24th Schrödinger European User Group Meeting

Tue, 12 May 2026 08:00:00 -0400 - 1 day ago

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Thu, 07 May 2026 08:00:00 -0400 - 6 days ago

Evogene Schedules First Quarter 2026 Financial Results Release

Evogene price target raised to $2.25 from $1.75 at Alliance Global

2026-04-13T14:21:10.000Z - 4 weeks ago

Evogene price target raised to $2.25 from $1.75 at Alliance Global

Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price

2026-04-02T21:27:08.000Z - 5 weeks ago

Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price

Evogene receives Nasdaq minimum bid price notification

2026-04-02T20:05:46.000Z - 5 weeks ago

Evogene receives Nasdaq minimum bid price notification

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Thu, 02 Apr 2026 16:01:00 -0400 - 5 weeks ago

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Tue, 31 Mar 2026 08:00:00 -0400 - 6 weeks ago

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Evogene files to sell 5.08M ordinary shares for holders

2026-03-26T20:35:48.000Z - 6 weeks ago

Evogene files to sell 5.08M ordinary shares for holders

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline

2026-03-14T01:01:01.000Z - 2 months ago

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline

Q4 2025 Evogene Ltd Earnings Call Transcript

2026-03-13T23:50:52.000Z - 2 months ago

Q4 2025 Evogene Ltd Earnings Call Transcript

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

2026-03-13T15:40:44.000Z - 2 months ago

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Mon, 09 Mar 2026 09:00:00 -0400 - 2 months ago

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Evogene Earnings Call Transcript: Q4 2025

Mar 5, 2026, 9:00 AM EST - 2 months ago

Evogene Earnings Call Transcript: Q4 2025

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

2026-03-05T12:41:07.000Z - 2 months ago

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

Evogene Earnings Review: Q4 Summary

2026-03-05T12:10:35.000Z - 2 months ago

Evogene Earnings Review: Q4 Summary

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

2026-03-05T12:09:46.000Z - 2 months ago

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 07:00:00 -0500 - 2 months ago

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

An Overview of Evogene's Earnings

2026-03-04T19:01:57.000Z - 2 months ago

An Overview of Evogene's Earnings

Evogene Releases CEO Letter to Shareholders

Wed, 25 Feb 2026 08:00:00 -0500 - 2 months ago

Evogene Releases CEO Letter to Shareholders

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Thu, 19 Feb 2026 08:00:00 -0500 - 2 months ago

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

2026-02-17T13:33:51.000Z - 3 months ago

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

2026-02-17T13:10:12.000Z - 3 months ago

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Tue, 17 Feb 2026 08:00:00 -0500 - 3 months ago

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Wed, 11 Feb 2026 08:00:00 -0500 - 3 months ago

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

Tue, 10 Feb 2026 13:20:00 -0500 - 3 months ago

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

2026-02-10T13:29:55.000Z - 3 months ago

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

2026-02-10T13:16:48.000Z - 3 months ago

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

GOOG GOOGL

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Tue, 10 Feb 2026 08:00:00 -0500 - 3 months ago

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Evogene Appoints Prof. John Irwin and Prof.

Mon, 09 Feb 2026 08:00:00 -0500 - 3 months ago

Evogene Appoints Prof. John Irwin and Prof.

Evogene (EVGN) Subsidiary Biomica Secures Licensing Deal for Innovative Cancer Therapy

2026-02-05T11:26:12.000Z - 3 months ago

Evogene (EVGN) Subsidiary Biomica Secures Licensing Deal for Innovative Cancer Therapy

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

2026-02-05T11:00:14.000Z - 3 months ago

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Wed, 04 Feb 2026 22:00:00 -0500 - 3 months ago

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Evogene (EVGN) Signs Licensing Agreement for Promising Cancer Therapy

2026-02-04T13:41:08.000Z - 3 months ago

Evogene (EVGN) Signs Licensing Agreement for Promising Cancer Therapy

Biomica and Lishan Biotech sign licensing agreement for BMC128

2026-02-04T13:05:13.000Z - 3 months ago

Biomica and Lishan Biotech sign licensing agreement for BMC128

Evogene (EVGN) and Unravel Biosciences Partner to Tackle Neurological Diseases

2026-01-07T12:30:48.000Z - 4 months ago

Evogene (EVGN) and Unravel Biosciences Partner to Tackle Neurological Diseases

Evogene, Unravel Biosciences announce scientific collaboration

2026-01-07T12:15:13.000Z - 4 months ago

Evogene, Unravel Biosciences announce scientific collaboration

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Wed, 07 Jan 2026 07:00:00 -0500 - 4 months ago

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Evogene appoints Nissan as VP of Business Development

2025-12-30T12:10:49.000Z - 4 months ago

Evogene appoints Nissan as VP of Business Development

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Tue, 30 Dec 2025 07:00:00 -0500 - 4 months ago

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Evogene Earnings Call Transcript: Q3 2025

Nov 20, 2025, 9:00 AM EST - 6 months ago

Evogene Earnings Call Transcript: Q3 2025

Evogene Reports Third Quarter 2025 Financial Results

Thu, 20 Nov 2025 07:00:00 -0500 - 6 months ago

Evogene Reports Third Quarter 2025 Financial Results

What's Next: Evogene's Earnings Preview

2025-11-19T16:03:33.000Z - 6 months ago

What's Next: Evogene's Earnings Preview

Evogene’s Casterra and Fantini announce strategic collaboration

2025-11-11T12:11:04.000Z - 6 months ago

Evogene’s Casterra and Fantini announce strategic collaboration

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Tue, 11 Nov 2025 07:00:00 -0500 - 6 months ago

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Evogene Schedules Third Quarter 2025 Financial Results Release

Thu, 06 Nov 2025 09:00:00 -0500 - 6 months ago

Evogene Schedules Third Quarter 2025 Financial Results Release

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Thu, 28 Aug 2025 07:00:00 -0400 - 9 months ago

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Evogene reports Q2 EPS (10c) vs. (5c) last year

2025-08-22T09:55:14.000Z - 9 months ago

Evogene reports Q2 EPS (10c) vs. (5c) last year

Evogene Earnings Call Transcript: Q2 2025

Aug 19, 2025, 9:00 AM EDT - 9 months ago

Evogene Earnings Call Transcript: Q2 2025

Evogene reports Q2 cont ops EPS (50c) vs. (85c) last year

2025-08-19T11:10:51.000Z - 9 months ago

Evogene reports Q2 cont ops EPS (50c) vs. (85c) last year

Evogene Reports Second Quarter 2025 Financial Results

Tue, 19 Aug 2025 07:00:00 -0400 - 9 months ago

Evogene Reports Second Quarter 2025 Financial Results

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Aug 12, 2025, 7:00 AM EDT - 9 months ago

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Evogene Schedules Second Quarter 2025 Financial Results Release

Jul 29, 2025, 7:00 AM EDT - 10 months ago

Evogene Schedules Second Quarter 2025 Financial Results Release

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

ICL

Evogene announces completion of generative AI foundation model with Google Cloud

2025-06-10T11:15:40.000Z - 1 year ago

Evogene announces completion of generative AI foundation model with Google Cloud

GOOG GOOGL

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Evogene price target lowered to $3.50 from $6 at Alliance Global Partners

2025-06-06T14:55:12.000Z - 1 year ago

Evogene price target lowered to $3.50 from $6 at Alliance Global Partners

Evogene price target lowered to $3.50 from $5 at Lake Street

2025-05-22T12:45:28.000Z - 1 year ago

Evogene price target lowered to $3.50 from $5 at Lake Street

Evogene Reports First Quarter 2025 Financial Results

May 21, 2025, 7:00 AM EDT - 1 year ago

Evogene Reports First Quarter 2025 Financial Results

Evogene Schedules First Quarter 2025 Financial Results Release

May 8, 2025, 7:00 AM EDT - 1 year ago

Evogene Schedules First Quarter 2025 Financial Results Release

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Apr 21, 2025, 7:00 AM EDT - 1 year ago

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 7:15 AM EST - 1 year ago

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Mar 6, 2025, 7:00 AM EST - 1 year ago

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Feb 20, 2025, 7:00 AM EST - 1 year ago

Evogene Schedules Fourth Quarter 2024 Financial Results Release

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Feb 13, 2025, 8:00 AM EST - 1 year ago

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Evogene Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 7:30 AM EST - 1 year ago

Evogene Reports Third Quarter 2024 Financial Results

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Nov 19, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Nov 12, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Evogene Schedules Third Quarter 2024 Financial Results Release

Nov 7, 2024, 7:00 AM EST - 1 year ago

Evogene Schedules Third Quarter 2024 Financial Results Release

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Aug 23, 2024, 8:55 AM EDT - 1 year ago

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Evogene Reports Second Quarter 2024 Financial Results

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Evogene Reports Second Quarter 2024 Financial Results

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Aug 12, 2024, 7:11 AM EDT - 1 year ago

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Schedules Second Quarter 2024 Financial Results Release

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Evogene Schedules Second Quarter 2024 Financial Results Release

Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split

Jul 23, 2024, 8:48 AM EDT - 1 year ago

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split

ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants

Jul 17, 2024, 8:00 AM EDT - 1 year ago

ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants

ICL

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat

Jul 2, 2024, 7:00 AM EDT - 2 years ago

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat

Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

May 23, 2024, 11:00 AM EDT - 2 years ago

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

SuperBusa
SuperBusa May. 11 at 4:08 PM
$EVGN next Wednesday earings.
0 · Reply
SuperBusa
SuperBusa May. 7 at 3:49 PM
$EVGN
0 · Reply
omenkes
omenkes May. 4 at 6:53 PM
$EVGN https://www.biomicamed.com/ read the message. why have they not officially published the full results? Asco 2026 is at the end of the month. will it be published there (like in 2022, 2024)? https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS2685 - june 2, 2022 https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8631 - may 29, 2024 what will it be in 2026?
1 · Reply
omenkes
omenkes Apr. 23 at 2:41 PM
$EVGN https://www.greenqueen.com.hk/finally-foods-pre-seed-funding-molecular-farming-casein-protein-potatoes/ https://www.proteinproductiontechnology.com/post/finally-foods-closes-pre-seed-round-to-scale-plant-based-casein-production-in-potatoes Finally foods is partly owned by Evogene and the casein expression is first implementation of the evogene ai for genetic modifications. And we still are waiting for the Biomica phase 1 final results of bmc128. interim in 2024 was very promising.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 14 at 11:40 PM
$EVGN RSI: 41.67, MACD: -0.0146 Vol: 0.04, MA20: 0.82, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:26 PM
$EVGN says it has until September 28, 2026 to fix its minimum bid problem after Nasdaq's notice.
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 31 at 12:03 PM
$EVGN Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock
0 · Reply
ObsidianClaw
ObsidianClaw Mar. 31 at 9:59 AM
$EVGN 🗑️
0 · Reply
100K2022
100K2022 Mar. 25 at 10:57 PM
$EVGN looks like dud
0 · Reply
SuperBusa
SuperBusa Mar. 25 at 4:58 PM
$EVGN
0 · Reply
WastedJake
WastedJake Mar. 25 at 2:37 PM
$EVGN lol
0 · Reply
Fenerium_x
Fenerium_x Mar. 24 at 8:23 PM
$EVGN @STOCKSGambino does company presented anything today?
0 · Reply
100K2022
100K2022 Mar. 24 at 7:24 PM
$EVGN WTF?
0 · Reply
STOCKSGambino
STOCKSGambino Mar. 23 at 5:00 PM
$EVGN https://x.com/StocksGambino/status/2036125448850026630
0 · Reply
WastedJake
WastedJake Mar. 20 at 7:54 PM
$EVGN im in
0 · Reply
STOCKSGambino
STOCKSGambino Mar. 20 at 4:46 PM
$EVGN
1 · Reply
RiZzBoTt
RiZzBoTt Mar. 19 at 5:18 PM
$EVGN If @STOCKSGambino is in, im definitely in. As always do your own research.
0 · Reply
KAMIKAZ3TIGER
KAMIKAZ3TIGER Mar. 19 at 5:07 PM
$EVGN $5 in 2026!!!
0 · Reply
STOCKSGambino
STOCKSGambino Mar. 19 at 4:19 PM
$EVGN https://x.com/StocksGambino/status/2034665876293640429
1 · Reply
STOCKSGambino
STOCKSGambino Mar. 19 at 2:48 PM
$EVGN Reminder EVGN has this next week; - ''Oral presentation titled "Drug Discovery and Development: Evogene" scheduled for March 24, 2026, 15:30–15:45 WET. Evogene Ltd. will present its pharma discovery achievements at the BIO-Europe Spring 2026 conference in Lisbon.'' they started their 2nd collab with Google in Feb so they will prob mention Google again; - ''Successful collaboration with Google Cloud, leading to a second collaboration to integrate advanced AI agents.''
0 · Reply
suntanner20
suntanner20 Mar. 19 at 12:24 PM
$EVGN Casterra.co is 100% owned by Evogene. Its castor seeds for biofuel. in talks with $XOM and $CVX for full biofuel production in Brazil. OIL above 100 per bar could crush shorts to 5.00 per share $AZN + $EVGN ChempassAI = 10 per share they both have the same programs so its a natural fit.
0 · Reply
STOCKSGambino
STOCKSGambino Mar. 18 at 2:45 PM
$EVGN https://x.com/StocksGambino/status/2034279845866144251
0 · Reply